New Hope for Progressive Supranuclear Palsy with Innovative Trial | UC San Francisco
A $75.4 million NIH grant enables a UCSF-led clinical trial testing three drugs for progressive supranuclear palsy (PSP), aiming to slow its progression. The trial, involving up to 50 sites, uses a platform model to quickly identify effective therapies, prioritizing enrollment of diverse populations. CurePSP collaborates in recruitment, offering hope for patients and families.
Reference News
A $75.4 million NIH grant enables a UCSF-led clinical trial testing three drugs for progressive supranuclear palsy (PSP), aiming to slow its progression. The trial, involving up to 50 sites, uses a platform model to quickly identify effective therapies, prioritizing enrollment of diverse populations. CurePSP collaborates in recruitment, offering hope for patients and families.
A $75.4 million grant-funded clinical trial at UCSF will test three drugs concurrently for progressive supranuclear palsy (PSP), aiming to slow its progression. The trial, emphasizing diverse enrollment and offering financial support, uses an innovative platform model to efficiently test new therapies, offering hope for PSP patients.